LABT Lakewood-Amedex Biotherapeutics Inc. stock chart & analysis
Conviction 45Scan · Wed, Nov 4, 2026Lakewood-Amedex Biotherapeutics Inc. (LABT) closed at $0.1926 (-1.23%) on Nov 4, 2026. Price is below its 50-day. RSI(14) 17, -99.8% from its 52-week high, -99.8% year to date. Sector: Pharmaceutical Preparations.
Why LABT moved
From the StockSetups movers recaps that covered LABT, newest first. A recap states what was known that day.
- Premarket+224.2%
According to a Yahoo Finance headline dated this morning, Lakewood-Amedex Biotherapeutics is highlighting its Nu-3 Resistance Data in response to the National Action Plan of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria.
Premarket Stock Movers — July 22, 2026: Why LABT, INLF, INM, CHAI & ZCMD Are Surging →
Financials as of Tue, Jun 30, 2026 · quarterly.
LABT technical analysis
Trend
It closed 84.8% below the 50-day ($1.27). ADX(14) at 49 points to a strong, established trend.
Momentum
RSI(14) is 17, in oversold territory. The MACD histogram is positive. A bullish RSI divergence is in place.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $1.2M a day on average. ATR(14) is $0.1015, 52.7% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (0.12) shows accumulation.
Key levels
The chart pattern's support is $0.4648 and its resistance $1.52. The 52-week range is $0.1687 to $88.38; price is 99.8% below the high and 14.2% above the low. The VWAP anchored at the 52-week high is $3.16, above price.
Performance
LABT returned -32.4% (1 week), -77.8% (1 month), -91.4% (3 months), -99.3% (6 months), -99.8% (year to date).
About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Pharmaceutical Preparations · Listed 2026
Insider activity
SEC Form 4 transactions in LABT
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Tucker Joseph Edward Director · Warrant to acquire Common Stock · 2026-04-24 | Grant | 33.78K | $0 | 2026-04-24 | 2026-05-06 |
SEC filings
EDGAR filings in LABT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.